Cheung Hoi Yu
Direktor/Vorstandsmitglied bei YNBY INTERNATIONAL LIMITED
Aktive Positionen von Cheung Hoi Yu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SIRNAOMICS LTD. | Direktor/Vorstandsmitglied | 01.07.2021 | - |
Independent Dir/Board Member | 01.07.2021 | - | |
KEEN VISION ACQUISITION CORPORATION | Direktor/Vorstandsmitglied | 01.10.2021 | - |
Independent Dir/Board Member | 01.10.2021 | - | |
YNBY INTERNATIONAL LIMITED | Direktor/Vorstandsmitglied | 21.11.2023 | - |
Independent Dir/Board Member | 21.11.2023 | - | |
Sun Yat-Sen Cultural Foundation Ltd. | Direktor/Vorstandsmitglied | - | - |
The Stock Exchange of Hong Kong Ltd.
The Stock Exchange of Hong Kong Ltd. Investment Banks/BrokersFinance HKEx is the holding company of The Stock Exchange of Hong Kong Limited, Hong Kong Futures Exchange Limited and Hong Kong Securities Clearing Company Limited. It brings together the market organisations which have transformed Hong Kong's financial services industry from a domestically focused market to become a central market place in Asia attracting investment funds from all over the world. HKEx was listed in June 2000 following the integration of Hong Kong's securities and derivatives markets. As a market-driven organisation, answerable to its shareholders, HKEx competes vigorously for opportunities in the region and around the world. HKEx's operations are organised into focused units, directly supervised and controlled by management and the board of directors. The board, the highest decision-making body, determines HKEx's objectives, missions, strategies, policies and business plan and monitors their implementation by management. In its role as the operator and frontline regulator of the central securities and derivatives marketplace in Hong Kong, HKEx regulates listed issuers; administers listing, trading and clearing rules; and provides services, primarily at the wholesale level, to customers of the exchanges and clearing houses, including issuers and intermediaries - investment banks or sponsors, securities and derivatives brokers, custodian banks and information vendors - who service the investor directly. These services comprise trading, clearing and settlement, depository and nominee services, and information services. | Corporate Officer/Principal | 01.04.2018 | - |
Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd.
Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sirnaomics, Inc., Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. is a Chinese company that develops nucleic acid drugs. The company is based in Suzhou, China. The company was founded in 2008 by Yang Lu, David Mark Evans. Yang Lu has been the CEO since 2008. | Direktor/Vorstandsmitglied | - | - |
Independent Dir/Board Member | - | - | |
Dna-Tech Ltd. | Direktor/Vorstandsmitglied | - | - |
Angenomics Ltd. | Direktor/Vorstandsmitglied | - | - |
Hong Kong Dna Chips Ltd. | Direktor/Vorstandsmitglied | 01.04.2007 | - |
Gründer | 01.04.2007 | - | |
░░░░ ░░░░░░░░░░░ ░░░░░ ░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░ ░░░░ ░░░░ ░░░░░░░ ░░░░░░░░░░ ░ ░░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░ ░░░░ ░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░ ░░░░ ░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░ ░░░░ ░░░░ ░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░ ░░░░ ░░░░░░░░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░░░░ ░░░ ░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░ ░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Karriereverlauf von Cheung Hoi Yu
Ehemalige bekannte Positionen von Cheung Hoi Yu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
░░░░ ░░░░ ░░░░░░░ ░░░ ░░░░░░░ ░ ░░░░░░░░░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░ ░░░░░░░ ░ ░░░░░░░░░░ ░░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░ ░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░ ░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░░ ░░░░ ░░░░░░░░░░ ░░ ░░░░░░░ ░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Cheung Hoi Yu
University of Saskatchewan | Doctorate Degree |
Statistik
International
Hong Kong | 16 |
China | 7 |
Vereinigte Staaten | 4 |
Operativ
Director/Board Member | 20 |
Independent Dir/Board Member | 6 |
Corporate Officer/Principal | 5 |
Sektoral
Finance | 6 |
Consumer Services | 6 |
Health Technology | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
SIRNAOMICS LTD. | Health Technology |
KEEN VISION ACQUISITION CORPORATION | Finance |
YNBY INTERNATIONAL LIMITED | Finance |
Private Unternehmen | 20 |
---|---|
Hong Kong Science & Technology Parks Corp.
Hong Kong Science & Technology Parks Corp. Miscellaneous Commercial ServicesCommercial Services Hong Kong Science & Technology Parks Corp. provides research and development in fields of science and technology. It helps the science and technology companies under its care by offering them both state-of-the-art facilities as well as value-added services including research and development offices, infrastructure, market-led laboratories, and technical centres with professional support services. The company was founde din 2002 and is headquartered in Hong Kong. | Commercial Services |
CR-CP Life Science Fund
CR-CP Life Science Fund Investment ManagersFinance CR-CP Life Science Fund is a venture capital fund invests companies located in China. It targets companies operating in the fields of diagnose, medical equipment and health technology. | Finance |
Hong Kong Council For Testing & Certification | |
Gordon Research Conferences | |
Asian Fund For Cancer Research Ltd. | |
Hong Kong Biotechnology Organization | |
Hai Kang Life Corp. Ltd.
Hai Kang Life Corp. Ltd. Medical/Nursing ServicesHealth Services Hai Kang Life Corp. Ltd. operates as a healthcare platform. The Chinese company was founded by Cheung Hoi Yu and Cheung Hoi Yu has been the CEO since incorporation. | Health Services |
Tiger Jade Acquisition Co.
Tiger Jade Acquisition Co. Financial ConglomeratesFinance Tiger Jade Acquisition Co. is a blank check company. It engages in the business of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 5, 2022 and is headquartered in Hong Kong. | Finance |
Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Allia | |
The Hong Kong Chinese Importers' & Exporters' Association | |
Hong Kong-Taiwan Youth Exchange Promotion Association Ltd. | |
Sun Yat-Sen Cultural Foundation Ltd. | |
Hong Kong Dna Chips Ltd. | |
Angenomics Ltd. | |
Dna-Tech Ltd. | |
Chinese Neuroscience Society | |
Beijing Society For Neuroscience | |
Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd.
Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sirnaomics, Inc., Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. is a Chinese company that develops nucleic acid drugs. The company is based in Suzhou, China. The company was founded in 2008 by Yang Lu, David Mark Evans. Yang Lu has been the CEO since 2008. | Health Technology |
The Stock Exchange of Hong Kong Ltd.
The Stock Exchange of Hong Kong Ltd. Investment Banks/BrokersFinance HKEx is the holding company of The Stock Exchange of Hong Kong Limited, Hong Kong Futures Exchange Limited and Hong Kong Securities Clearing Company Limited. It brings together the market organisations which have transformed Hong Kong's financial services industry from a domestically focused market to become a central market place in Asia attracting investment funds from all over the world. HKEx was listed in June 2000 following the integration of Hong Kong's securities and derivatives markets. As a market-driven organisation, answerable to its shareholders, HKEx competes vigorously for opportunities in the region and around the world. HKEx's operations are organised into focused units, directly supervised and controlled by management and the board of directors. The board, the highest decision-making body, determines HKEx's objectives, missions, strategies, policies and business plan and monitors their implementation by management. In its role as the operator and frontline regulator of the central securities and derivatives marketplace in Hong Kong, HKEx regulates listed issuers; administers listing, trading and clearing rules; and provides services, primarily at the wholesale level, to customers of the exchanges and clearing houses, including issuers and intermediaries - investment banks or sponsors, securities and derivatives brokers, custodian banks and information vendors - who service the investor directly. These services comprise trading, clearing and settlement, depository and nominee services, and information services. | Finance |
Taide Pharmaceutical (Zhejiang) Co., Ltd.
Taide Pharmaceutical (Zhejiang) Co., Ltd. BiotechnologyHealth Technology Medtide, Inc. is a peptide focused contract research, development and manufacturing organization. It services include contract research organization services, namely peptide new chemical entity discovery synthesis, contract development and manufacturing organization services, namely peptide chemistry, manufacturing and controls development, and contract manufacturing organization services, namely peptide NCE and generic drug commercial manufacturing. The company was founded by Li Xiang and Xu Qi on June 11, 2020 and is headquartered in Shaoxing, China. | Health Technology |
- Börse
- Insiders
- Cheung Hoi Yu
- Erfahrung